arrow Log In to View Account     |          

Thursday, May 17th at 9:00 PM ET

Presenters: James Wheeler, PharmD, BCPS
and Kira Brice Harris, PharmD, BCPS, CDE, CPP

This webcast will provide live credit (L) for those states requiring it.

Emerging insulin combination therapies, including glucagon-like peptide 1 receptor agonists (GLP-1RAs)/insulin fixed-dose combinations (FDCs), have the capacity to address a number of unmet treatment needs that persist among patients with type 2 diabetes mellitus (T2DM). These novel agents offer improved A1c control with reduced potential for hypoglycemia and weight gain and less stringent injection requirements. Community pharmacists represent ideal clinicians to, not only, educate patients about their diabetes therapeutic regimens and inform evidence-based treatment decisions, but also to facilitate improvements in self-management, adherence, and appropriate utilization of GLP-1RA/insulin FDCs, among other T2DM treatments. As such, it is essential that pharmacists understand the clinical utility of these new therapies and are able to effectively implement practical strategies to educate patients on the injection principles of combination agents and on overall T2DM self-management.

This webcast activity will provide the most up-to-date clinical evidence of the rationale, efficacy, and safety of fixed-dose GLP-1RA/insulin combinations as a treatment strategy for patients with T2DM. It will also provide community pharmacist-driven strategies to assess patient eligibility for these therapies, manage patients using these therapies, as well as provide appropriate and effective education about the injection devices and self-injection techniques.

This activity has been designed to meet the needs of community pharmacists, as well as other pharmacists who manage patients with T2DM. No prerequisites required.

  • Introduction:
    Overcoming Challenges in Diabetes Control Utilizing Conventional Agents
  • Patient Case Introduction
  • GLP1-RA/Insulin Fixed-Ratio Combinations:
    Whom Are They Indicated for? What Are the Benefits? What Are the Risks?
  • Reviewing Patient Cases:
    Focusing on Practical Management and Counseling Points
  • Considerations for Administration, Counseling/Educating, and Managing Adverse Events of Fixed-Dose Combination GLP1-RA/Insulin
  • Practical Considerations:
    Advanced Scenarios that May Be Seen in Practice
  • Conclusions and Q & A
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
  • COMPARE the safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of select injectable diabetes agents including basal insulin, GLP-1Ras, and fixed-dose combination GLP-1RA/insulin products.
  • IDENTIFY patients who may benefit from GLP-1RA/insulin combinations.
  • DISCUSS differences between injection devices and self-injection protocols of available GLP-1RA/insulin combination agents.
  • DEVELOP strategies to educate patients on diabetes management and appropriate use of GLP-1RA/insulin delivery devices.
James Wheeler, PharmD, BCPS
Assistant Professor Clinical Pharmacy and Translational Science
Director of Continuing Professional Development
College of Pharmacy
University of Tennessee Health Science Center
Nashville, Tennessee

Kira Brice Harris, PharmD, BCPS, CDE, CPP
Clinical Pharmacy Specialist
Novant Health Family Medicine Residency Clinic
Associate Professor
Wingate University School of Pharmacy
Wingate, North Carolina

acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.5 live contact hours of credit (0.15 CEU) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. A statement of CE credit will be mailed within 4 weeks following successful completion of the educational activity. UAN: 0064-0000-18-201-L01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website:
To receive credit for your participation in this activity, all pharmacists must include their CORRECT NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.

A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

There is no fee for this educational activity.

<img src="" alt="procced to pretest" border="0" />
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.